US Market News
4月前
Allurion Announces Exercise of Warrants for $3.0 Million in Gross ProceedsFebruary 24, 2026 9:15 AM
Business Wire
Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warrants and February 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-286837) and the shares of common stock issuable upon exercise of the November 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-292660). The aggregate gross proceeds from the exercise of the Existing Warrants is expected to total approximately $3.0 million, before deducting financial advisory fees. The closing of the offering is expected to occur on or about February 25, 2026, subject to satisfaction of customary closing conditions.
Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The new warrants will be exercisable into an aggregate of up to 5,319,130 shares of common stock, will be exercisable beginning on the effective date of stockholder approval of the shares issuable upon exercise of the new warrants at an exercise price of $1.15 per share, and have a term of exercise equal to five years after the stockholder approval date.
The securities offered in the private placement have not been registered under the 1933 Act, or an applicable exemption under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement with the Securities and Exchange Commission to register the resale of the shares of common stock underlying the new warrants issued in the private placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule—the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss—with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
Forward-Looking Statements
This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected timing for the closing of this transaction, and the anticipated proceeds therefrom; the timing of stockholder approval of the shares underlying the new warrants; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.
Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, the size, timing and completion of the offering, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Gastric Balloon System, including the Allurion Smart Capsule; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Smart Capsule; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224024473/en/
Investor Contact
investors@allurion.com
Original: Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
iHub News
4月前
Allurion shares soar after FDA clears Smart Capsule weight-loss deviceFebruary 23, 2026 11:22 AM
IH Market News
Allurion Technologies (NYSE:ALUR) shares jumped about 40% after the company announced it had received U.S. Food and Drug Administration approval for its Allurion Gastric Balloon System, which includes the Allurion Smart Capsule.The FDA granted premarket approval for the weight-loss treatment, opening access to an estimated 80 million Americans with obesity who fall within the approved body mass index range of 30 to 40 kg/m², according to the company. Allurion noted that more than 100 million Americans are affected by obesity overall.The Allurion Smart Capsule is designed to be swallowed during a brief 15-minute office visit without the need for surgery, endoscopy, or anesthesia. Once in the stomach, the capsule is filled with fluid, remaining in place for roughly four months to promote fullness and reduced food intake. After that period, a patented Release Valve allows the device to empty and pass naturally through the body. Patients may begin a second treatment cycle two months after the first capsule exits.Internationally, the system has already been used by more than 200,000 patients, with outcomes documented in over 30 peer-reviewed medical publications. When paired with the company’s Virtual Care Suite, data indicate average total body weight loss of about 14%, rising above 20% after two treatment cycles.Allurion estimates that roughly 20 million Americans have started and discontinued GLP-1 weight-loss medications, a figure it expects could reach 40 million by 2027. Prior research cited by the company suggests around 65% of patients stop GLP-1 therapies within the first year, largely due to side effects.The Allurion Smart Capsule is protected by more than 50 patents worldwide and delivers approximately four months of treatment from a single administration, offering an alternative to daily or weekly drug-based regimens.Allurion Technologies stock price
Original: Allurion shares soar after FDA clears Smart Capsule weight-loss device
subslover
12月前
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical’s 40-year experience in the Canadian market and reflects Allurion’s commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss.
Minogue Medical has extensive experience in building high-performing medical networks across Canada. With a national ecosystem of dietitians, bariatric surgeons, and endoscopic specialists, the company ensures every patient journey is supported by highly qualified professionals who deliver a comprehensive program. Through its rigorous vetting and training processes, Minogue has become a trusted name in bringing advanced technologies into clinical practice.
“We select partners who share our vision for ethical, patient-centered care,” said Danny Minogue, CEO of Minogue Medical. “Allurion’s commitment to clinical rigor complements our approach, and together, we intend to set a new benchmark in Canadian weight management.”
Allurion is pioneering metabolically healthy weight loss, a new approach to obesity care focused on losing weight, keeping it off, and maintaining muscle. In partnership with Minogue Medical, Allurion will now be able to access providers who are committed to this approach and have demonstrated exceptional clinical results. In addition, the partnership is expected to increase access to providers offering a combination of the Allurion Program with GLP-1 therapy, to further enhance short and long-term results.
“Minogue Medical has built a strong reputation in Canada for its deep clinical expertise, strong network, and a proven ability to bring meaningful innovations to the field of metabolic and bariatric care,” said Dr. Michel Gagner, a leading Canadian bariatric surgeon. “Their multidisciplinary approach—engaging dietitians, surgeons, and endoscopists alike—ensures that patients are treated within a medically supervised, evidence-based framework. I am confident that this partnership represents a pivotal step forward for obesity care in Canada.”
“This agreement with Minogue Medical reflects our commitment to find partners globally who believe in our approach to obesity care,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We are looking forward to working with Minogue to develop the Canadian market and establish a new standard of care in the treatment of obesity.”
About Minogue Medical Inc.
subslover
1年前
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
Four abstracts presented at the European Congress on Obesity
Data indicate potential synergies of Allurion’s swallowable ProcedurelessTM intragastric balloon (the “Allurion Balloon”) and Virtual Care Suite (VCS) (together, the “Allurion Program”) with normal dosing of GLP-1s, building upon previous data on the combination of the Allurion Program with low-dose GLP-1s
GLP-1s used in combination with the VCS lead to an average of 6.1% increase in lean body mass, indicating that maintaining muscle may be possible even at normal doses for GLP-1s with Allurion’s AI-powered behavioral support
Allurion Balloon in combination with GLP-1s leads to an average of 21.2% reduction in body weight, potentially representing an option for patients with severe obesity seeking an alternative to bariatric surgery
2,000 patients using the Allurion Program without GLP-1s showed an average of 12.4% reduction in body weight with a 9.8% increase in muscle mass, underscoring the safety and effectiveness of the Allurion Balloon as a standalone therapy
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass preservation.
In one study of 138 patients prescribed GLP-1s with normal dose escalation who used the VCS, patients increased lean body mass by an average of 6.1%, increased muscle mass by an average of 6.4%, and decreased fat mass by an average of 10.2% after four months of using the VCS, indicating that Allurion’s AI-driven behavioral support may help patients maintain muscle, even at normal or high doses of GLP-1 therapy.
In another study of 60 patients who were treated with the Allurion Balloon and then semaglutide, patients achieved an average of 21.2% reduction in total body weight and improvements in metabolic parameters over a 10-month period. This combination therapy approach led to outcomes similar to those achieved with bariatric surgery.1
“The combination of the Allurion Program and semaglutide represents a significant advancement in weight loss,” said Dr. Roberta Ienca, physician at Nuova Villa Claudia Clinic, Rome, Italy, who oversaw this study. “While using low doses of semaglutide in combination with the Allurion Program may be preferable in most patients, there is a role for using normal dosing and escalation schedules as well, especially in patients with severe obesity seeking an alternative to bariatric surgery. This innovative approach may also address the challenges of weight regain often seen with the use of GLP-1 medications alone, potentially providing a more sustainable path to achieving and maintaining a healthier weight.”
Two other studies pertaining to the Allurion Program were also presented at ECO.
In one study, 43 patients prescribed GLP-1s who used the VCS achieved an average of 17.3% reduction in total body weight at nine months. Improved weight loss outcomes were observed in this study compared to the weight loss observed in US studies where the VCS was not used. Such other studies reported an average of 15.2% total body weight loss for patients prescribed tirzepatide and an average of 7.9% total body weight loss for patients prescribed semaglutide, each at 12 months2. These outcomes suggest that AI-driven interventions can play a crucial role in augmenting traditional treatment methods.
In another study, which was a large single-center experience of 2000 patients treated between 2017 and 2024 with the Allurion Program, patients achieved an average weight reduction of 12.4% after four months with an average of 9.8% increase in muscle mass after six months. These results demonstrate a potentially safe, effective, and scalable program for obesity clinics.
Details of the Presentations are as follows:
Title: Optimizing Body Composition and Lean Mass Preservation: The Value of AI-Powered Digital Platforms and Health Coaches for Patients on GLP-1 Medications
Presenter: Bill Nadeau, RD, Vice President, Medical Affairs, Allurion
Title: The New Era of Combination Weight Loss Treatments: The Swallowable Gastric Balloon Program and the Anti-Obesity Medication Semaglutide
Title: Enhancing Weight Loss Outcomes with GLP-1 Medications: The Role of AI-Powered Digital Platforms and Health Coaches
Presenter: Bill Nadeau, RD, Vice President, Medical Affairs, Allurion
Presenter: Roberta Ienca, MD, Weight Management Center, Nuova Villa Claudia Clinic, Rome, Italy
Title: Exceptional Outcomes and Safety Profile in the First 2,000 Patients Treated with the Allurion Balloon Program at a Single Spanish Bariatric Center
Presenter: Adelardo Caballero, MD, Instituto de Obesidad, Madrid, Spain
About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “target,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the expected benefit of a combination approach of the Allurion Program and GLP-1 use for weight loss management, market acceptance of such new combined therapies, the uniqueness of Allurion’s product and service offerings and other statements about future events that reflect the current beliefs and assumptions of Allurion’s manage
subslover
1年前
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.
52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 medication through 8 months.
“I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages,” said Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch who oversaw this case series. “These results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects—including muscle wasting—and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.”
Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost1 and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit2, due in part to side effects, dose escalation required for continued weight loss, and cost. Semaglutide dosing is typically increased to 2.4mg, over two times higher than the maximum dose of 1.0mg used in the combination approach.
“Muscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests that a combination approach that leverages Allurion’s full program—which includes the balloon, our Virtual Care Suite, and our behavior change program—may be a compelling solution,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.”
Additional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.
subslover
1年前
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.
“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care.”
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Forward-Looking Statements
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Renee
1週前
glenn1919
3月前
ErnieBilco
3月前
Doubledown75
4月前
tedpeele
1年前
TrendTrade2016
1年前
TheFinalCD
1年前
PonkenPlonken
1年前
Monksdream
1年前
Penny chatter
2年前
メールアドレスで登録
